Indiana has joined in settling two whistleblower lawsuits against Walgreens. Indiana Attorney General Curtis Hill says the agreements resolve allegations that Walgreens knowingly over-dispensed insulin pens to Medicare and Medicaid beneficiaries and billed Medicaid for certain drugs at higher-than-allowed rates.
Walgreens will pay $209.2 million in the insulin pen settlement, with $89.1 million going to the state Medicaid programs. Indiana Medicaid is set to receive $2.9 million. The company also sold certain drugs at higher prices in its Prescription Savings Club, which enabled Walgreens to recoup more money from state Medicaid programs than it was entitled. Under the Discount Drug Pricing Settlement, Walgreens will pay $60 million, with nearly $30 million going to state Medicaid programs. Indiana Medicaid will receive $953,742.96.
A National Association of Medicaid Fraud Control Unit Team including representatives from the Office of the Indiana Attorney General conducted settlement negotiations on behalf of the states.